KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Finished Goods (2018 - 2025)

Historic Finished Goods for Alnylam Pharmaceuticals (ALNY) over the last 8 years, with Q4 2025 value amounting to $32.3 million.

  • Alnylam Pharmaceuticals' Finished Goods rose 2233.95% to $32.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $32.3 million, marking a year-over-year increase of 2233.95%. This contributed to the annual value of $32.3 million for FY2025, which is 2233.95% up from last year.
  • Alnylam Pharmaceuticals' Finished Goods amounted to $32.3 million in Q4 2025, which was up 2233.95% from $38.8 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Finished Goods registered a high of $38.8 million during Q3 2025, and its lowest value of $7.0 million during Q4 2021.
  • In the last 5 years, Alnylam Pharmaceuticals' Finished Goods had a median value of $25.4 million in 2022 and averaged $23.6 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Finished Goods crashed by 4481.21% in 2021, and later surged by 26553.89% in 2022.
  • Alnylam Pharmaceuticals' Finished Goods (Quarter) stood at $7.0 million in 2021, then skyrocketed by 265.54% to $25.6 million in 2022, then decreased by 1.89% to $25.1 million in 2023, then rose by 5.21% to $26.4 million in 2024, then rose by 22.34% to $32.3 million in 2025.
  • Its Finished Goods stands at $32.3 million for Q4 2025, versus $38.8 million for Q3 2025 and $33.7 million for Q2 2025.